A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs AZP 531 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Alize Pharma
- 29 Oct 2015 Results published in an Alize Pharma media release.
- 29 Oct 2015 Status changed from active, no longer recruiting to completed according to an Alize Pharma media release.
- 17 Jun 2015 Planned End Date changed from 1 Nov 2014 to 1 Oct 2015 as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History